InterMed Discovery and Axxam Announce Joint Research Agreement for the Identification of Novel Natural Functional Ingredients
InterMed Discovery (IMD) and Axxam SpA announced that their joint research efforts have proved to be successful in providing a technology platform that offers, in addition to screening solutions, the discovery of natural bioactive compounds. These bioactive compounds are particularly valuable to companies in the food, beverages, flavour and fragrance industries.
Based on these results, both companies have therefore signed a second partnership agreement to further combine the expert platforms of IMD and Axxam. The combined technology platform offers an integrated approach to the screening, discovery and profiling of innovative natural sources-derived functional ingredients for various life science applications.
The joint research will focus on the mutual discovery and validation of Flavour/Fragrance functional ingredients, which will then be offered to food, beverages, flavour and fragrance companies. The proprietary compounds that are discovered will have clearly defined activity profiles and naturally-derived chemical properties, making them much more valuable to the customers wishing to utilize them.
This joint research initiative between IMD and Axxam deepens an already existing strategic alliance, which was established in 2007 to provide complete service solutions for the identification of bioactive compounds from natural sources to the flavor and fragrance industries.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Infection defense: call for support by the killer cells

Innovative microscopy technique reveals secrets of lipid synthesis inside cells - Two-color infrared photothermal microscopy (2C-IPM) opens new avenues for long-term study of lipid metabolism in living cells

Copper destroys MRSA at a touch
Hypoproteinemia
Chemotherapy
Purac to build new plant for biomedical resorbable polymers in the USA
Camille_Guérin

The weight of pollution: exposure linked to obesity - Chronic exposure to environmental pollutants found to increase risk of cardiovascular disease

Merck Opens New € 29 Million Biologics Testing Center in Shanghai - First-of-its-kind facility for Merck in China to meet local demand

LUMiFuge® | Stability analyzers | LUM
Testing the Efficacy of New Gene Therapies More Efficiently
